CYT 303
Alternative Names: CYT-303Latest Information Update: 09 Jun 2023
At a glance
- Originator Cytovia Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural cytotoxicity triggering receptor 1 agonists; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver cancer; Solid tumours
Most Recent Events
- 14 Apr 2023 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical studies in liver cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 14 Apr 2023 Pharmacodynamics data from preclinical trial in liver cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 11 Dec 2022 Cytovia Therapeutics plans to submit IND for Liver cancer (monotherapy) in 2023 (Cytovia Therapeutics pipeline, December 2022)